Billerica, MA 2/26/09—Millipore has announced the purchase of the assets associated with Epitome Biosystems’ EpiTag technology for an undisclosed price. Designed for use on Luminex’s xMAP platform, EpiTag technology utilizes informatics to develop specific and selective antibodies for intra-cellular targets. “The EpiTag technology will allow us to develop multiplex immunoassays for cellular targets that were previously very difficult to detect and quantify. As a result, we will enable customers to leverage the power of the Luminex xMAP platform for cell signaling by providing antibodies and kits that are specific to the highest areas of interest for researchers,” stated Rick Ryan, vice president of Millipore’s Drug Discovery Business Unit. Millipore also plans to develop other profiling technologies using the technology.